Climb Bio (CLYM) Shares Outstanding (Diluted Average) (2021 - 2026)

Climb Bio has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $68.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 1.1% year-over-year to $68.2 million; the trailing twelve-month figure through Mar 2026 stood at $68.2 million (up 1.1% YoY), and the FY2025 full-year result was $67.8 million, up 40.8% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $68.2 million, up from $67.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $68.2 million in Q1 2026, with the low at $26.2 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $41.1 million across 5 years, with a median of $27.6 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) soared 656.55% — and 2023, when it increased 0.97%.
• Climb Bio's Shares Outstanding (Diluted Average) stood at $26.3 million in 2022, then climbed by 2.57% to $27.0 million in 2023, then surged by 78.47% to $48.2 million in 2024, then surged by 40.8% to $67.8 million in 2025, then increased by 0.58% to $68.2 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $68.2 million (Q1 2026), $67.8 million (Q4 2025), and $68.0 million (Q3 2025), per Business Quant data.